CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' (DEFICIT) EQUITY (UNAUDITED) - USD ($) $ in Thousands | Total | Common Stock | Accumulated Deficit |
Balance, beginning of period at Jan. 28, 2023 | $ 29,773 | $ 175,450 | $ (145,677) |
Balance, beginning of period (in shares) at Jan. 28, 2023 | | 12,754,368 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Restricted stock issued (in shares) | | 86,824 | |
Net share settlement of restricted stock units | (76) | $ (76) | |
Net share settlement of restricted stock units (in shares) | | (28,294) | |
Stock-based compensation expense | 490 | $ 490 | |
Net Income (Loss) | (12,107) | | (12,107) |
Balance, end of period at Apr. 29, 2023 | 18,080 | $ 175,864 | (157,784) |
Balance, end of period (in shares) at Apr. 29, 2023 | | 12,812,898 | |
Balance, beginning of period at Jan. 28, 2023 | 29,773 | $ 175,450 | (145,677) |
Balance, beginning of period (in shares) at Jan. 28, 2023 | | 12,754,368 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Net Income (Loss) | (31,471) | | |
Balance, end of period at Jul. 29, 2023 | $ (1,160) | $ 175,988 | (177,148) |
Balance, end of period (in shares) at Jul. 29, 2023 | 12,917,373 | 12,917,373 | |
Balance, beginning of period at Apr. 29, 2023 | $ 18,080 | $ 175,864 | (157,784) |
Balance, beginning of period (in shares) at Apr. 29, 2023 | | 12,812,898 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Restricted stock issued (in shares) | | 104,475 | |
Stock-based compensation expense | 124 | $ 124 | |
Net Income (Loss) | (19,364) | | (19,364) |
Balance, end of period at Jul. 29, 2023 | $ (1,160) | $ 175,988 | (177,148) |
Balance, end of period (in shares) at Jul. 29, 2023 | 12,917,373 | 12,917,373 | |
Balance, beginning of period at Feb. 03, 2024 | $ 3,124 | $ 176,552 | (173,428) |
Balance, beginning of period (in shares) at Feb. 03, 2024 | 12,926,022 | 12,926,022 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Restricted stock issued (in shares) | | 134,597 | |
Net share settlement of restricted stock units | $ (51) | $ (51) | |
Net share settlement of restricted stock units (in shares) | | (21,641) | |
Stock-based compensation expense | 292 | $ 292 | |
Net Income (Loss) | (8,830) | | (8,830) |
Balance, end of period at May. 04, 2024 | (5,465) | $ 176,793 | (182,258) |
Balance, end of period (in shares) at May. 04, 2024 | | 13,038,978 | |
Balance, beginning of period at Feb. 03, 2024 | $ 3,124 | $ 176,552 | (173,428) |
Balance, beginning of period (in shares) at Feb. 03, 2024 | 12,926,022 | 12,926,022 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Net Income (Loss) | $ (23,334) | | |
Balance, end of period at Aug. 03, 2024 | $ (19,705) | $ 177,057 | (196,762) |
Balance, end of period (in shares) at Aug. 03, 2024 | 13,111,638 | 13,111,638 | |
Balance, beginning of period at May. 04, 2024 | $ (5,465) | $ 176,793 | (182,258) |
Balance, beginning of period (in shares) at May. 04, 2024 | | 13,038,978 | |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | | | |
Restricted stock issued (in shares) | | 72,660 | |
Stock-based compensation expense | 264 | $ 264 | |
Net Income (Loss) | (14,504) | | (14,504) |
Balance, end of period at Aug. 03, 2024 | $ (19,705) | $ 177,057 | $ (196,762) |
Balance, end of period (in shares) at Aug. 03, 2024 | 13,111,638 | 13,111,638 | |